Immune-Related Adverse Effects of Cancer Immunotherapy— Implications for Rheumatology

Research output: Contribution to journalReview article

Abstract

Immune checkpoint inhibitors (ICIs) are increasingly studied and used as therapy for a growing number of malignancies. ICIs work by blocking inhibitory pathways of T-cell activation, leading to an immune response directed against tumors. Such nonspecific immunologic activation can lead to immune-related adverse events (IRAEs). Some IRAEs, including inflammatory arthritis, sicca syndrome, myositis, and vasculitis, are of special interest to rheumatologists. As use of ICIs increases, recognition of these IRAEs and developing treatment strategies will become important. In this review, the current literature on rheumatic and musculoskeletal IRAEs is summarized. The incidence, clinical presentations, and treatment considerations are highlighted.

Original languageEnglish (US)
Pages (from-to)65-78
Number of pages14
JournalRheumatic Disease Clinics of North America
Volume43
Issue number1
DOIs
StatePublished - Feb 1 2017

Fingerprint

Rheumatology
Immunotherapy
Neoplasms
Myositis
Sjogren's Syndrome
Vasculitis
Arthritis
Therapeutics
T-Lymphocytes
Incidence

Keywords

  • Arthritis
  • Immune checkpoint inhibitors
  • Immune-related adverse events
  • Malignancy
  • Sicca syndrome

ASJC Scopus subject areas

  • Rheumatology

Cite this

@article{6fb009e27fc744a2926c1f47ee84f169,
title = "Immune-Related Adverse Effects of Cancer Immunotherapy— Implications for Rheumatology",
abstract = "Immune checkpoint inhibitors (ICIs) are increasingly studied and used as therapy for a growing number of malignancies. ICIs work by blocking inhibitory pathways of T-cell activation, leading to an immune response directed against tumors. Such nonspecific immunologic activation can lead to immune-related adverse events (IRAEs). Some IRAEs, including inflammatory arthritis, sicca syndrome, myositis, and vasculitis, are of special interest to rheumatologists. As use of ICIs increases, recognition of these IRAEs and developing treatment strategies will become important. In this review, the current literature on rheumatic and musculoskeletal IRAEs is summarized. The incidence, clinical presentations, and treatment considerations are highlighted.",
keywords = "Arthritis, Immune checkpoint inhibitors, Immune-related adverse events, Malignancy, Sicca syndrome",
author = "Laura Cappelli and Ami Shah and Clifton Bingham",
year = "2017",
month = "2",
day = "1",
doi = "10.1016/j.rdc.2016.09.007",
language = "English (US)",
volume = "43",
pages = "65--78",
journal = "Rheumatic Disease Clinics of North America",
issn = "0889-857X",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - Immune-Related Adverse Effects of Cancer Immunotherapy— Implications for Rheumatology

AU - Cappelli, Laura

AU - Shah, Ami

AU - Bingham, Clifton

PY - 2017/2/1

Y1 - 2017/2/1

N2 - Immune checkpoint inhibitors (ICIs) are increasingly studied and used as therapy for a growing number of malignancies. ICIs work by blocking inhibitory pathways of T-cell activation, leading to an immune response directed against tumors. Such nonspecific immunologic activation can lead to immune-related adverse events (IRAEs). Some IRAEs, including inflammatory arthritis, sicca syndrome, myositis, and vasculitis, are of special interest to rheumatologists. As use of ICIs increases, recognition of these IRAEs and developing treatment strategies will become important. In this review, the current literature on rheumatic and musculoskeletal IRAEs is summarized. The incidence, clinical presentations, and treatment considerations are highlighted.

AB - Immune checkpoint inhibitors (ICIs) are increasingly studied and used as therapy for a growing number of malignancies. ICIs work by blocking inhibitory pathways of T-cell activation, leading to an immune response directed against tumors. Such nonspecific immunologic activation can lead to immune-related adverse events (IRAEs). Some IRAEs, including inflammatory arthritis, sicca syndrome, myositis, and vasculitis, are of special interest to rheumatologists. As use of ICIs increases, recognition of these IRAEs and developing treatment strategies will become important. In this review, the current literature on rheumatic and musculoskeletal IRAEs is summarized. The incidence, clinical presentations, and treatment considerations are highlighted.

KW - Arthritis

KW - Immune checkpoint inhibitors

KW - Immune-related adverse events

KW - Malignancy

KW - Sicca syndrome

UR - http://www.scopus.com/inward/record.url?scp=85001610237&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85001610237&partnerID=8YFLogxK

U2 - 10.1016/j.rdc.2016.09.007

DO - 10.1016/j.rdc.2016.09.007

M3 - Review article

VL - 43

SP - 65

EP - 78

JO - Rheumatic Disease Clinics of North America

JF - Rheumatic Disease Clinics of North America

SN - 0889-857X

IS - 1

ER -